Parkinson's Disease Clinical Trial
Official title:
A Forced Cycling Exercise Program in Individuals With Parkinson's Disease: Can it Improve Gait Parameters?
NCT number | NCT02175082 |
Other study ID # | STU00093757 |
Secondary ID | |
Status | Terminated |
Phase | N/A |
First received | |
Last updated | |
Start date | June 2014 |
Est. completion date | June 2019 |
Verified date | October 2020 |
Source | Shirley Ryan AbilityLab |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The purpose of this study is to assess the effectiveness of a forced exercise aerobic exercise program, utilizing a cycling activity, on specific gait parameters and balance in individuals with Parkinson's Disease (PD). Design: pilot, feasibility, randomized control, evaluator blinded. Subjects: Twenty four patients with idiopathic PD Hoehn and Yahr (H&Y) stage II or III. Intervention: Participants randomly assigned to one of two exercise groups, forced exercise or self selected exercise, on cycling machine three times a week for 8 weeks. Both groups to exercise at same aerobic intensity level to keep heart rate at 60-80% heart rate max. Outcomes: Gait parameters of step length, width, and variability as measured by the GAITRite; 6 Minute Walk Test; mini-BESTest (balance testing); exercise tolerance via Patient Reported Outcomes Measurement Information System (PROMIS) scale.
Status | Terminated |
Enrollment | 12 |
Est. completion date | June 2019 |
Est. primary completion date | June 2019 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 30 Years to 80 Years |
Eligibility | Inclusion Criteria: - Idiopathic Parkinson's Disease - Hoehn and Yahr Stages II - III. - Ages 30-80 years - Medical Clearance - Ability to understand and the willingness to sign a written informed consent. Exclusion Criteria: - MOCA: (Montreal Cognition Scale) : rating of less than 24, indicative of cognitive dysfunction - Changes in Parkinson's medications within the two weeks prior to starting the study - Anticipated change in Parkinson Disease medications during the course of the study - Uncontrolled orthostasis - Symptomatic coronary artery disease - Fracture of lower limb within 6 months prior to study onset or significant lower limb orthopedic diagnosis that would limit cycling - Other significant neurologic diagnoses including multiple sclerosis or vestibular disease - Acute illness - Physical therapy within the month prior to study entry - Subjects already participating in a forced exercise or high intensity exercise program - Any medical condition that the physician investigator determined would compromise safety. |
Country | Name | City | State |
---|---|---|---|
United States | Shirley Ryan AbilityLab (formerly the Rehabilitation Institute of Chicago) | Chicago | Illinois |
Lead Sponsor | Collaborator |
---|---|
Shirley Ryan AbilityLab | Northwestern Memorial Hospital, Paul Ruby Foundation for Parkinson's Research |
United States,
Sung P, Rafferty M, Doyle L, Kliver E, Bines K, Traines J, Scarpa A, Marciniak C, Solanki S, Todd A. Technology-based Forced Paced Cycling in Parkinson's disease: Is it Feasible and Effective?Archives of PM&R October 2019Volume 100, Issue 10, Page e126
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Steps per day | Subjects steps per day will be measured with a Garmin wrist step counter | Over 8 week trial and for 2 months post intervention | |
Primary | 6-minute walk test | Distance walked in 6 minutes | 8 weeks | |
Secondary | Stride length | Length of stride in meters as measured by the GAITrite | 8 weeks | |
Secondary | Step Width | Width of step in meters as measured by the GAITrite | 8 weeks | |
Secondary | Step variability | Standard deviation of step as measure in meters by the Gaitrite system | 8 weeks | |
Secondary | 10 meter walk test | Time in seconds for the subject to walk 10 meters | 8 weeks | |
Secondary | miniBESTest (Balance Evaluation Systems Test) | Subject is scored as the 14 activities on this scale are performed, and a summary score is derived. | 8 weeks |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02915848 -
Long-term Stability of LFP Recorded From the STN and the Effects of DBS
|
||
Recruiting |
NCT03648905 -
Clinical Laboratory Evaluation of Chronic Autonomic Failure
|
||
Terminated |
NCT02688465 -
Effect of an Apomorphine Pump on the Quality of Sleep in Parkinson's Disease Patients (POMPRENELLE).
|
Phase 4 | |
Completed |
NCT05040048 -
Taxonomy of Neurodegenerative Diseases : Observational Study in Alzheimer's Disease and Parkinson's Disease
|
||
Active, not recruiting |
NCT04006210 -
Efficacy, Safety and Tolerability Study of ND0612 vs. Oral Immediate Release Levodopa/Carbidopa (IR-LD/CD) in Subjects With Parkinson's Disease Experiencing Motor Fluctuations
|
Phase 3 | |
Completed |
NCT02562768 -
A Study of LY3154207 in Healthy Participants and Participants With Parkinson's Disease
|
Phase 1 | |
Completed |
NCT00105508 -
Sarizotan HC1 in Patients With Parkinson's Disease Suffering From Treatment-associated Dyskinesia
|
Phase 3 | |
Completed |
NCT00105521 -
Sarizotan in Participants With Parkinson's Disease Suffering From Treatment Associated Dyskinesia
|
Phase 3 | |
Recruiting |
NCT06002581 -
Repetitive Transcranial Magnetic Stimulation(rTMS) Regulating Slow-wave to Delay the Progression of Parkinson's Disease
|
N/A | |
Completed |
NCT02236260 -
Evaluation of the Benefit Provided by Acupuncture During a Surgery of Deep Brain Stimulation
|
N/A | |
Completed |
NCT00529724 -
Body Weight Gain, Parkinson, Subthalamic Stimulation
|
Phase 2 | |
Active, not recruiting |
NCT05699460 -
Pre-Gene Therapy Study in Parkinson's Disease and Multiple System Atrophy
|
||
Completed |
NCT03703570 -
A Study of KW-6356 in Patients With Parkinson's Disease on Treatment With Levodopa-containing Preparations
|
Phase 2 | |
Completed |
NCT03462680 -
GPR109A and Parkinson's Disease: Role of Niacin in Outcome Measures
|
N/A | |
Completed |
NCT02837172 -
Diagnosis of PD and PD Progression Using DWI
|
||
Not yet recruiting |
NCT04046276 -
Intensity of Aerobic Training and Neuroprotection in Parkinson's Disease
|
N/A | |
Recruiting |
NCT02952391 -
Assessing Cholinergic Innervation in Parkinson's Disease Using the PET Imaging Marker [18F]Fluoroethoxybenzovesamicol
|
N/A | |
Active, not recruiting |
NCT02937324 -
The CloudUPDRS Smartphone Software in Parkinson's Study.
|
N/A | |
Completed |
NCT02874274 -
Vaccination Uptake (VAX) in PD
|
N/A | |
Terminated |
NCT02924194 -
Deep Brain Stimulation of the nbM to Treat Mild Cognitive Impairment in Parkinson's Disease
|
N/A |